This inventor holds 1 USPTO granted patent. Top assignee: Eli Lilly and Company. Active years: 2000.
Company Filing History:
Years Active: 2000
Title: The Innovative Contributions of Daniel Wierda
Introduction
Daniel Wierda is a notable inventor based in Greenfield, IN (US). He has made significant contributions to the field of therapeutic treatments for autoimmune diseases. His work focuses on methods for inhibiting the activation and proliferation of T cells and B cells, which are crucial in the treatment of autoimmune conditions.
Latest Patents
Wierda holds a patent for a therapeutic treatment aimed at autoimmune diseases. The patent details methods for inhibiting the activation and/or proliferation of T cells and B cells. It particularly highlights the use of the isozyme selective PKC inhibitor, (S)-3,4-[N, N'-1,1'-((2'-ethoxy)-3''(O)-4''-(N,N-dimethylamino)-butane)-bis-(3,3'-indolyl 1)]-1(H)-pyrrole-2,5-dione and its pharmaceutically acceptable salts.
Career Highlights
Daniel Wierda is currently employed at Eli Lilly and Company, where he continues to advance his research and innovations. His work at this prominent pharmaceutical company allows him to contribute to the development of new treatments that can improve the lives of patients suffering from autoimmune diseases.
Collaborations
Wierda collaborates with Douglas Kirk Ways, a fellow professional in the field. Their partnership enhances the research and development efforts at Eli Lilly and Company, fostering innovation in therapeutic solutions.
Conclusion
Daniel Wierda's contributions to the field of autoimmune disease treatment exemplify the impact of innovative thinking in medicine. His patent and ongoing work at Eli Lilly and Company highlight the importance of research in developing effective therapies.